In a patient with a 10‑year history of heavy smoking (20‑30 cigarettes per day), currently on aspirin 75 mg daily, who has completed a 12‑month course of prasugrel and is maintained on a statin plus ezetimibe regimen with LDL‑C at 60 mg/dL, what is the most important intervention?

Smoking Cessation is the Most Critical Intervention

For this patient with a 10+ year history of heavy smoking (20-30 cigarettes/day), smoking cessation is unequivocally the most important intervention, even with optimal medical therapy already in place. While the patient's antiplatelet regimen (aspirin after completing prasugrel) and lipid management (statin/ezetimibe with LDL-C at 60 mg/dL) are appropriate, continued smoking fundamentally undermines all other cardiovascular risk reduction efforts.

Why Smoking Cessation Takes Priority

Smoking directly counteracts antiplatelet therapy effectiveness. Research demonstrates that cigarette smoking increases platelet aggregability, and low-dose aspirin (75 mg daily, as this patient is taking) cannot effectively inhibit the heightened platelet activity in smokers with coronary heart disease 1. This means the patient's aspirin therapy is substantially less effective while smoking continues. Studies show that in CHD patients who smoke, the increased platelet aggregability induced by tobacco cannot be adequately suppressed by standard aspirin doses 1, 2.

Smoking perpetuates atherosclerotic disease progression despite optimal lipid control. Even with excellent LDL-C management at 60 mg/dL, ongoing tobacco exposure promotes endothelial dysfunction, inflammation, and plaque instability—negating much of the benefit from statin therapy 3.

Current Medical Regimen Assessment

The patient's existing therapy is guideline-concordant:

• Aspirin 75 mg daily: Appropriate long-term maintenance dose after completing 12 months of dual antiplatelet therapy 4, 5, 6
• Completed prasugrel course: The 12-month duration of prasugrel following ACS/PCI with stenting meets Class I recommendations 4, 5, 7
• Statin + ezetimibe with LDL-C 60 mg/dL: Exceeds the guideline target of <70 mg/dL for secondary prevention, though <55 mg/dL is increasingly recommended for very high-risk patients 8, 9

Actionable Smoking Cessation Strategy

Immediate steps 3:

1. Assess readiness to quit at every clinical encounter

2. Develop a structured cessation plan including:

   • Setting a quit date within 2-4 weeks
   • Behavioral counseling (individual or group programs)
   • Pharmacotherapy: nicotine replacement therapy (patch, gum, lozenge) AND/OR bupropion or varenicline
   • Referral to specialized smoking cessation programs

3. Arrange systematic follow-up with scheduled check-ins at 1 week, 1 month, and 3 months post-quit date

4. Address environmental tobacco smoke exposure at home and work

Critical Pitfalls to Avoid

• Do not assume the patient "knows" smoking is harmful—provide specific, personalized data about how smoking undermines their current medications
• Do not delay cessation counseling because other risk factors are controlled—smoking cessation provides benefits within weeks to months
• Do not offer cessation as optional—frame it as the single most important medical intervention available

Secondary Considerations

While smoking cessation is paramount, consider:

• Aspirin dose optimization: If the patient continues smoking despite intervention, consider increasing aspirin to 100-325 mg daily or adding back a P2Y12 inhibitor (clopidogrel 75 mg), as higher doses or dual therapy may be needed to overcome smoking-induced platelet hyperreactivity 1
• LDL-C target: Current level of 60 mg/dL is good, but achieving <55 mg/dL (or even <40 mg/dL for very high-risk) could provide additional benefit 8, 9

The evidence is unambiguous: no medication regimen, regardless of how optimal, can compensate for continued tobacco use in a patient with established coronary disease. Smoking cessation must be the primary focus of this patient's care.